Dirk Klingbiel - Concepedia

Author

Dirk Klingbiel

Swiss Group For Clinical Cancer Research ORCID

Also Known As

D KLINGBIEL, D Klingbiel, D. Klingbiel, Dirk Klingbiel, Klingbiel, D., Klingbiel, Dirk

144

Publications

5.5K

Citations

H-Index

Concepts

All Affiliations

Swiss Group For Clinical Cancer Research Kantonsspital St. Gallen University Hospital of Zurich Kantonsspital Graubünden University Hospital of Basel

About

Dirk Klingbiel is an author at Swiss Group For Clinical Cancer Research specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	23	30	2.2K
2	Health Sciences	7	7	287
3	Nursing	1	1	126
4	Public Health	1	1	126
5	Biostatistics	1	1	76

Dirk Klingbiel

Publications

Citations

H-Index

Page 1

	Year	Citations
Prognostic Role of <i>KRAS</i> and <i>BRAF</i> in Stage II and III Resected Colon Cancer: Results of the Translational Study on the PETACC-3, EORTC 40993, SAKK 60-00 Trial Arnaud Roth, Sabine Tejpar, Mauro Delorenzi, Journal of Clinical Oncology	2009	1.1K
Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features Edoardo Missiaglia, Bart Jacobs, G. d'Ario, Annals of Oncology Proximal Colon CancersGastrointestinal OncologyMedicineGastroenterologyPathology	2014	655
Integrated Analysis of Molecular and Clinical Prognostic Factors in Stage II/III Colon Cancer A. Roth, Mauro Delorenzi, Sabine Tejpar, JNCI Journal of the National Cancer Institute	2012	276
Prognosis of stage II and III colon cancer treated with adjuvant 5-fluorouracil or FOLFIRI in relation to microsatellite status: results of the PETACC-3 trial Dirk Klingbiel, Zacharenia Saridaki, A. Roth, Annals of Oncology Stage IiGastrointestinal OncologyMedicinePetacc-3 TrialPathology	2014	235
Final Results of a Prospective Evaluation of the Predictive Value of Interim Positron Emission Tomography in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP-14 (SAKK 38/07) Christoph Mamot, Dirk Klingbiel, Felicitas Hitz, Journal of Clinical Oncology	2015	183
Phase 2 Trial of Single-agent Everolimus in Chemotherapy-naive Patients with Castration-resistant Prostate Cancer (SAKK 08/08) Arnoud J. Templeton, Valérie Dutoit, Richard Cathomas, European Urology UrologyGenitourinary CancerMedicineSakk 08/08Pharmacology	2013	129
The effect of real-time electronic monitoring of patient-reported symptoms and clinical syndromes in outpatient workflow of medical oncologists: E-MO AIC, a multicenter cluster-randomized phase III study (SAKK 95/06) Florian Strasser, David Blum, Roger von Moos, Annals of Oncology NursingClinical SystemOutpatient WorkflowRemote Patient MonitoringPatient Management	2015	126
Activity of Platinum-Based Chemotherapy in Patients With Advanced Prostate Cancer With and Without DNA Repair Gene Aberrations Sabine Schmid, Aurelius Omlin, Celestia S. Higano, JAMA Network Open	2020	109
Organ-specific response to nivolumab in patients with non-small cell lung cancer (NSCLC) Sabine Schmid, Stefan Diem, Qiyu Li, Cancer Immunology Immunotherapy Organ-specific ResponseMedicineImmune Checkpoint InhibitorCancer TreatmentOncology	2018	107
A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma Christoph Renner, Pier Luigi Zinzani, Rémy Gressin, Haematologica	2012	97

Page 1